BACKGROUND: Postsurgical pain control can have a significant impact on patient outcomes and hospital-associated costs. We sought to evaluate the effect of intercostal nerve blocks using liposomal bupivacaine on length of stay (LOS) in patients undergoing video-assisted thoracoscopic surgery (VATS). METHODS: We retrospectively reviewed outcomes in 80 patients undergoing VATS wedge resection, VATS lobectomy, or minimally-invasive esophagectomy (MIE). Patients received either liposomal bupivacaine (n=40) or standard-release bupivacaine with epinephrine (n=40) via intercostal nerve block. The LOS, 24-hour postoperative pain scores, overall opioid usage, and patient ambulation rates at 24 hours were compared for the two groups. RESULTS: The median LOS was significantly shorter in patients receiving liposomal bupivacaine, at 1.35 days (IQR, 1.28 to 1.53 days) compared to 2.45 days (IQR, 2.08 to 3.51 days) in patients receiving standard-release bupivacaine (P<0.0001). Average post-operative pain score during the first 24 hours was 3.4±1.8 for the liposomal bupivacaine group and 2.3±1.2 for the control group (P=0.002). This difference, though statistically significant, is likely not clinically significant, as there was no difference in 24-hour postoperative intravenous morphine equivalent usage between the liposomal bupivacaine and control groups (29.8±21.0 vs. 31.9±20.9 mg, respectively, P=0.664). Interestingly, however, 93% (37/40) of patients receiving liposomal bupivacaine were able to ambulate within 24-hours after surgery, compared to 65% (26/40) of patients in the control group (P=0.003). CONCLUSIONS: The use of liposomal bupivacaine is associated with decreased LOS in postoperative thoracic surgery patients and earlier return to ambulation. It does not, however, decrease 24-hour postoperative pain scores or opioid usage.
BACKGROUND: Postsurgical pain control can have a significant impact on patient outcomes and hospital-associated costs. We sought to evaluate the effect of intercostal nerve blocks using liposomal bupivacaine on length of stay (LOS) in patients undergoing video-assisted thoracoscopic surgery (VATS). METHODS: We retrospectively reviewed outcomes in 80 patients undergoing VATS wedge resection, VATS lobectomy, or minimally-invasive esophagectomy (MIE). Patients received either liposomal bupivacaine (n=40) or standard-release bupivacaine with epinephrine (n=40) via intercostal nerve block. The LOS, 24-hour postoperative pain scores, overall opioid usage, and patient ambulation rates at 24 hours were compared for the two groups. RESULTS: The median LOS was significantly shorter in patients receiving liposomal bupivacaine, at 1.35 days (IQR, 1.28 to 1.53 days) compared to 2.45 days (IQR, 2.08 to 3.51 days) in patients receiving standard-release bupivacaine (P<0.0001). Average post-operative pain score during the first 24 hours was 3.4±1.8 for the liposomal bupivacaine group and 2.3±1.2 for the control group (P=0.002). This difference, though statistically significant, is likely not clinically significant, as there was no difference in 24-hour postoperative intravenous morphine equivalent usage between the liposomal bupivacaine and control groups (29.8±21.0 vs. 31.9±20.9 mg, respectively, P=0.664). Interestingly, however, 93% (37/40) of patients receiving liposomal bupivacaine were able to ambulate within 24-hours after surgery, compared to 65% (26/40) of patients in the control group (P=0.003). CONCLUSIONS: The use of liposomal bupivacaine is associated with decreased LOS in postoperative thoracic surgery patients and earlier return to ambulation. It does not, however, decrease 24-hour postoperative pain scores or opioid usage.
Entities:
Keywords:
Liposomal bupivacaine; length of stay (LOS); regional anesthesia; thoracoscopy
Authors: Salvatore A Parascandola; Jessica Ibañez; Graham Keir; Jacqueline Anderson; Michael Plankey; Deanna Flynn; Candice Cody; Lorenzo De Marchi; Marc Margolis; M Blair Marshall Journal: Interact Cardiovasc Thorac Surg Date: 2017-06-01
Authors: David C Rice; Juan P Cata; Gabriel E Mena; Andrea Rodriguez-Restrepo; Arlene M Correa; Reza J Mehran Journal: Ann Thorac Surg Date: 2015-04-23 Impact factor: 4.330
Authors: Kamal G Khalil; Mina L Boutrous; Adel D Irani; Charles C Miller; Timothy R Pawelek; Anthony L Estrera; Hazim J Safi Journal: Ann Thorac Surg Date: 2015-10-24 Impact factor: 4.330
Authors: Daniel R Butz; Deana S Shenaq; Veronica L M Rundell; Brittany Kepler; Eric Liederbach; Jeff Thiel; Catherine Pesce; Glenn S Murphy; Mark Sisco; Michael A Howard Journal: Plast Reconstr Surg Glob Open Date: 2015-06-05
Authors: Benjamin G Domb; Asheesh Gupta; Jon E Hammarstedt; Christine E Stake; Kinzie Sharp; John M Redmond Journal: BMC Musculoskelet Disord Date: 2014-09-24 Impact factor: 2.362
Authors: Haydee Del Calvo; Duc T Nguyen; Leonora M Meisenbach; Ray Chihara; Edward Y Chan; Edward A Graviss; Min P Kim Journal: J Thorac Dis Date: 2020-05 Impact factor: 2.895
Authors: Kian Banks; Sora Ely; Diana S Hsu; Dana A Dominguez; Rebecca C Gologorsky; Julia Wei; Clara Maxim; Simon K Ashiku; Ashish R Patel; Jeffrey B Velotta Journal: J Thorac Dis Date: 2022-01 Impact factor: 2.895